Of the rest of the 186 studies, 140 were excluded for the next factors: obstructive CAD (= 54), unclear or missing CFR data (= 21); usage of intravenous medicines (= 47); and imperfect info (= 18)

Of the rest of the 186 studies, 140 were excluded for the next factors: obstructive CAD (= 54), unclear or missing CFR data (= 21); usage of intravenous medicines (= 47); and imperfect info (= 18). CFR (SMD: 1.04; 95% CI: 0.51C1.58). Beta-blocker (SMD: 0.24; 95% CI: ?0.39C0.88) and ranolazine treatment (SMD: 0.31; 95% CI: ?0.39C1.01) weren’t connected with improved CFR. Conclusions: Therapy with ACEIs, ARBs, and statins was connected with improved CFR in individuals with suspicious or confirmed CMD. CCBs improved CFR among individuals followed for 6C12 weeks also. Ranolazine and Beta-blocker had zero effect on CFR. 0.05 was considered significant statistically. Outcomes Research Features and Selection A complete of 5,723 references had been identified from data source search analyses. Of the, 5,537 had been excluded during name and abstract level testing (Shape 1). Of the rest of the 186 research, 140 had been excluded for the next factors: obstructive CAD (= 54), unclear or lacking CFR data (= 21); usage of intravenous medicines (= 47); and imperfect info (= 18). Forty-six of the rest of the research reported CFR data and didn’t meet some other exclusion requirements, which 28 had been randomized controlled tests and 18 had been non-randomized studies. The scholarly research features are shown in Desk 1, and the medical characteristics of individuals are shown in Supplementary Desk 2. A complete of 845 individuals, which range from 8 to 55 individuals per trial, had been eventually included who received coronary microvascular function assessments before and after administration of oral medicaments. CFR is simple for coronary microvascular function evaluation (1), and we collected CFR data as an sign of coronary microvascular function therefore. At present, there is absolutely no standard gold regular for CFR recognition methods. Options for calculating CFR included intracoronary (IC) Doppler movement cable (= 6), cardiac magnetic resonance imaging (CMRI) (= 2), positron emission tomography (Family pet) (= 11), and Doppler echocardiography (DE) (= 27). Options for obtaining stenosis of epicardial coronary artery included intrusive angiography (= 21), CT coronary angiography (= 6), health background (= 8), and DE and home treadmill exercise check (= 11). Follow-up duration assorted from 0.75 to a year. Table 1 Research features. thead th valign=”best” align=”remaining” rowspan=”1″ colspan=”1″ Writer /th th valign=”best” align=”remaining” rowspan=”1″ colspan=”1″ Analysis /th th valign=”best” align=”remaining” rowspan=”1″ colspan=”1″ Way for CAD /th th valign=”best” align=”remaining” rowspan=”1″ colspan=”1″ Way for CFR /th th valign=”best” align=”remaining” rowspan=”1″ colspan=”1″ Medicines /th th valign=”best” align=”remaining” rowspan=”1″ colspan=”1″ Dosage /th th valign=”best” align=”middle” rowspan=”1″ colspan=”1″ Follow-up weeks /th th valign=”best” align=”middle” rowspan=”1″ colspan=”1″ em N /em /th th valign=”best” align=”middle” colspan=”2″ design=”border-bottom: slim solid #000000;” rowspan=”1″ Pre-CFR /th th valign=”best” align=”middle” colspan=”2″ design=”border-bottom: slim solid #000000;” rowspan=”1″ Post-CFR /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th valign=”best” align=”middle” colspan=”2″ rowspan=”1″ Mean SD /th th valign=”best” align=”middle” colspan=”2″ rowspan=”1″ Mean SD /th /thead RANDOMIZEDGolino et al. (26)After PCI, SCADInvasive angiogramDERanolazine750 mg/time0.7581.330.161.390.29Safdar et al. (27)CMDCTAPETRanolazine1,000C2,000 mg/time1211.60.31.90.4Villano et al. (23)CMDInvasive angiogramDERanolazine750 mg/time1151.990.61.860.5Zsuspend et al. (28)Cardiac symptoms XInvasive angiogramDEDiltiazem90 mg/time3.25222.190.582.50.72Fluvastatin40 mg/time3.25222.020.452.630.62Pauly et al. (9)CMDInvasive angiogramIC DopplerQuinapril40C80 mg/time4292.520.362.770.5Iino et al. (29)After PCI in RCA, sufferers without stenosis in LADInvasive angiogramIC DopplerCandesartan4C8 mg/time6.5141.990.23.370.27Chen et al. (21)Cardiac symptoms XInvasive angiogramIC DopplerEnalapril10 mg/time2103.260.564.010.65Toyama et al. (30)HTMedical historyCMRIOlmesartan10C40 mg/time6.5101.913.11.1Amlodipin2.5C10 mg/day6.5102.20.82.40.9Kamezaki et al. (31)HTClinical background and treadmill workout testDEValsartan40C80 mg/time1.582.340.383.041.09Nifedipine20C40 mg/time1.582.720.222.410.4Parodi et al. (32)HTInvasive angiogramPETEnalapril10C40 mg/time6.5102.420.722.370.59Verapamil240C480 mg/time6.5102.740.83.731.79Hinoi et al. (33)HTMedical historyDETelmisartan40 mg/time5202.40.42.90.4Nifedipine20 mg/time5202.50.32.50.3Xiaozhen et al. (34)HT&LVHInvasive angiogramDECarvedilol10 mg/time6.5282.310.313.160.67Metoprolol50 mg/time6.5292.320.292.460.58Gullu et al. (35)HTMedical historyDENebivolol5 mg/time2302.450.482.560.52Atenolol50 mg/time2302.460.442.210.4Buus et al. (36)HTMedical historyPETPerindopril4C8 mg/time12152.390.172.640.17Atenolol50C100 mg/day12152.310.162.090.19Yokoyama et al. (37)HCEchocardiography and fitness treadmill workout testPETSimvastatin5C10 mg/time10222.360.673.181.22Pravastatin10C20 mg/time10222.210.722.320.64Lario et al. (38)HCCTADEAtorvastatin40C80 mg/time3162.780.713.430.66Kawata et al. (39)DMEchocardiography and fitness treadmill workout testDETemocapril2 mg/time1122.740.283.310.36Candesartan8 mg/day1122.650.32.710.43Akinboboye et al. (40)HT&LVHClinical background and PETPETLisinopril10 mg/time1192.413.71.1NONRANDOMIZEDGalderisi et al. (41)HTMedical historyDENebivolol5 mg/time3202.070.162.20.243Eshtehardi et al. (42)SCADInvasive angiogramIC DopplerAtorvastatin40C80 mg/time6.5202.320.442.530.89Motz and Strauer (43)HT with microvascular anginaInvasive angiogramIC DopplerEnalapril10C20 mg/time3152.20.63.31.2Caliskan et.The principal outcome was change in CFR from baseline to follow-up after oral drug therapy. Outcomes: A complete of 46 research including 845 topics had been included in this scholarly study. this research. In accordance with baseline, the CFR was improved by angiotensin-converting enzymes (ACEIs), aldosterone receptor antagonists (ARBs) [regular indicate difference (SMD): 1.12; 95% CI: 0.77C1.47], and statins remedies (SMD: 0.61; 95%CI: 0.36C0.85). Six to a year of calcium route blocker (CCB) remedies improved CFR (SMD: 1.04; 95% CI: 0.51C1.58). Beta-blocker (SMD: 0.24; 95% CI: ?0.39C0.88) and ranolazine treatment (SMD: 0.31; 95% CI: ?0.39C1.01) weren’t connected with improved CFR. Conclusions: Therapy with ACEIs, ARBs, and statins was connected with improved CFR in sufferers with verified or dubious CMD. CCBs also improved CFR among sufferers implemented for 6C12 a few months. Beta-blocker and ranolazine acquired no effect on CFR. 0.05 was considered statistically significant. Outcomes Research Selection and Features A complete of 5,723 personal references had been identified from data source search analyses. Of the, 5,537 had been excluded during name and abstract level testing (Amount 1). Of the rest of the 186 research, 140 had been excluded for the next factors: obstructive CAD (= 54), unclear or lacking CFR data (= 21); usage of intravenous medications (= 47); and imperfect details (= 18). Forty-six of the rest of the research reported Goat polyclonal to IgG (H+L)(Biotin) CFR data and didn’t meet every other exclusion requirements, which 28 had been randomized controlled studies and 18 had been non-randomized studies. The analysis characteristics are provided in Desk 1, as well as the scientific characteristics of sufferers are provided in Supplementary Desk 2. A complete of 845 sufferers, which range from 8 to 55 individuals per trial, had been eventually included who received coronary microvascular function assessments before and after administration of oral medicaments. CFR is simple for coronary microvascular function evaluation (1), and we as a result gathered CFR data as an signal of coronary microvascular function. At the moment, there is absolutely no even gold regular for CFR recognition methods. Options for calculating CFR included intracoronary (IC) Doppler stream cable (= 6), cardiac magnetic resonance imaging (CMRI) (= 2), positron emission tomography (Family pet) (= 11), and Doppler echocardiography (DE) (= 27). Options for obtaining stenosis of epicardial coronary artery included intrusive angiography (= 21), CT coronary angiography (= 6), health background (= 8), and DE and fitness treadmill exercise check (= 11). Follow-up duration mixed from 0.75 to a year. Table 1 Research features. thead th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Writer /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Medical diagnosis /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Way for CAD /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Way HDAC-IN-7 for CFR /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Medications /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Dosage /th th valign=”best” align=”middle” rowspan=”1″ colspan=”1″ Follow-up a few months /th th valign=”best” align=”middle” rowspan=”1″ colspan=”1″ em N /em /th th valign=”best” align=”middle” colspan=”2″ design=”border-bottom: slim solid #000000;” rowspan=”1″ Pre-CFR /th th valign=”best” align=”middle” colspan=”2″ design=”border-bottom: slim solid #000000;” rowspan=”1″ Post-CFR /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th valign=”best” align=”middle” colspan=”2″ rowspan=”1″ Mean SD /th th valign=”best” align=”middle” colspan=”2″ rowspan=”1″ Mean SD /th /thead RANDOMIZEDGolino et al. (26)After PCI, SCADInvasive angiogramDERanolazine750 mg/time0.7581.330.161.390.29Safdar et al. (27)CMDCTAPETRanolazine1,000C2,000 mg/time1211.60.31.90.4Villano et al. (23)CMDInvasive angiogramDERanolazine750 mg/time1151.990.61.860.5Zsuspend et al. (28)Cardiac symptoms XInvasive angiogramDEDiltiazem90 mg/time3.25222.190.582.50.72Fluvastatin40 mg/time3.25222.020.452.630.62Pauly et al. (9)CMDInvasive angiogramIC DopplerQuinapril40C80 mg/time4292.520.362.770.5Iino et al. (29)After PCI in RCA, sufferers without stenosis in LADInvasive angiogramIC DopplerCandesartan4C8 mg/time6.5141.990.23.370.27Chen et al. (21)Cardiac symptoms XInvasive angiogramIC DopplerEnalapril10 mg/time2103.260.564.010.65Toyama et al. (30)HTMedical historyCMRIOlmesartan10C40 mg/time6.5101.913.11.1Amlodipin2.5C10 mg/day6.5102.20.82.40.9Kamezaki et al. (31)HTClinical background and treadmill workout testDEValsartan40C80 mg/time1.582.340.383.041.09Nifedipine20C40 mg/time1.582.720.222.410.4Parodi et al. (32)HTInvasive angiogramPETEnalapril10C40 mg/time6.5102.420.722.370.59Verapamil240C480 mg/time6.5102.740.83.731.79Hinoi et al. (33)HTMedical historyDETelmisartan40 mg/time5202.40.42.90.4Nifedipine20 mg/time5202.50.32.50.3Xiaozhen et al. (34)HT&LVHInvasive angiogramDECarvedilol10 mg/time6.5282.310.313.160.67Metoprolol50 mg/time6.5292.320.292.460.58Gullu et al. (35)HTMedical historyDENebivolol5 mg/time2302.450.482.560.52Atenolol50 mg/time2302.460.442.210.4Buus et al. (36)HTMedical historyPETPerindopril4C8 mg/time12152.390.172.640.17Atenolol50C100 mg/day12152.310.162.090.19Yokoyama et al. (37)HCEchocardiography and fitness treadmill workout testPETSimvastatin5C10 mg/time10222.360.673.181.22Pravastatin10C20 mg/time10222.210.722.320.64Lario et al. (38)HCCTADEAtorvastatin40C80 mg/time3162.780.713.430.66Kawata et al. (39)DMEchocardiography and fitness treadmill workout testDETemocapril2 mg/time1122.740.283.310.36Candesartan8 mg/day1122.650.32.710.43Akinboboye et al. (40)HT&LVHClinical background and PETPETLisinopril10 mg/time1192.413.71.1NONRANDOMIZEDGalderisi et al. (41)HTMedical historyDENebivolol5 mg/time3202.070.162.20.243Eshtehardi et al. (42)SCADInvasive angiogramIC DopplerAtorvastatin40C80 mg/time6.5202.320.442.530.89Motz and Strauer (43)HT with microvascular anginaInvasive angiogramIC DopplerEnalapril10C20 mg/time3152.20.63.31.2Caliskan et al. (44)Decrease coronary flowInvasive angiogramDEAtorvastatin20 mg/time2201.950.382.540.56Galderisi et al. (45)HTMedical historyDENebivolol5 mg/time1141.890.312.120.33Lethen et al. (46)HTClinical background, ECG, and DEPETIrbesartan600 mg/time3182.870.423.780.32Toms et al. (47)HTClinical background, ECG, and DEDECandesartan16 mg/time3223.113.561Sun et al. (48)HT, HCMedical historyDERosuvastatin10 mg/time12553.160.443.310.42Jensen et al. (49)HCInvasive angiogramIC DopplerSimvastatin40 mg/time12362.50.62.60.6Baller et al. (50)AnginaInvasive angiogramPETSimvastatin20 mg/time6.5232.20.62.640.6Schwartzkopff et al. (51)HTInvasive angiogramDEPerindopril4C8 mg/time12142.10.63.51.9Vogt and Strauer (52)HTInvasive angiogramDEDiltiazem242 35 mg/time12162.460.83.291.22Isradipine5.3 0.9 mg/day12152.330.553.30.87Fujimoto et al. (53)HCMedical historyDEFluvastatin20 mg/time31630.53.50.8Stamatelopoulos et al. (54)HTInvasive angiogramDEQuinapril20 mg/time1152.990.683.360.91Losartan100 mg/day1152.860.543.440.65Kjear et al. (55)DMTreadmill workout testPETLosartan100 mg/time6.5142.360.242.620.42Kawata et al. (56)DMDE and a fitness treadmill.She gave me the motivation to get this done extensive research. of calcium route blocker (CCB) remedies improved CFR (SMD: 1.04; 95% CI: 0.51C1.58). Beta-blocker (SMD: 0.24; 95% CI: ?0.39C0.88) and ranolazine treatment (SMD: 0.31; 95% CI: ?0.39C1.01) weren’t connected with improved CFR. Conclusions: Therapy with ACEIs, ARBs, and statins was connected with improved CFR in sufferers with verified or dubious CMD. CCBs also improved CFR among sufferers implemented for 6C12 a few months. Beta-blocker and ranolazine acquired no effect on CFR. 0.05 was considered statistically significant. Outcomes Research Selection and Features A complete of 5,723 sources had been identified from data source search analyses. Of the, 5,537 had been excluded during name and abstract level testing (Body 1). Of the rest of the 186 research, 140 had been excluded for the next factors: obstructive CAD (= 54), unclear or lacking CFR data (= 21); usage of intravenous medications (= 47); and imperfect details (= 18). Forty-six of the rest of the research reported CFR data and didn’t meet every other exclusion requirements, which 28 had been randomized controlled studies and 18 had been non-randomized studies. The analysis characteristics are provided in Desk 1, as well as the scientific characteristics of sufferers are provided in Supplementary Desk 2. A complete of 845 sufferers, which range from 8 to 55 individuals per trial, had been eventually included who received coronary microvascular function assessments before and after administration of oral medicaments. CFR is simple for coronary microvascular function evaluation (1), and we as a result gathered CFR data as an signal of coronary microvascular function. At the moment, there is absolutely no even gold regular for CFR recognition methods. Options for calculating CFR included intracoronary (IC) Doppler stream cable (= 6), cardiac magnetic resonance imaging (CMRI) (= 2), positron emission tomography (Family pet) (= 11), and Doppler echocardiography (DE) (= 27). Options for obtaining stenosis of HDAC-IN-7 epicardial coronary artery included intrusive angiography (= 21), CT coronary angiography (= 6), health background (= 8), and DE and fitness treadmill exercise check (= 11). Follow-up duration mixed from 0.75 to a year. Table 1 Research features. thead th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Writer /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Medical diagnosis /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Way for CAD /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Way for CFR /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Medications /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Dosage /th th valign=”best” align=”middle” rowspan=”1″ colspan=”1″ Follow-up a few months /th th valign=”best” align=”middle” rowspan=”1″ colspan=”1″ em N /em /th th valign=”best” align=”middle” colspan=”2″ design=”border-bottom: slim solid #000000;” rowspan=”1″ Pre-CFR /th th valign=”best” align=”middle” colspan=”2″ style=”border-bottom: thin solid #000000;” rowspan=”1″ Post-CFR /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th valign=”top” align=”center” colspan=”2″ rowspan=”1″ Mean SD /th th valign=”top” align=”center” colspan=”2″ rowspan=”1″ Mean SD /th /thead RANDOMIZEDGolino et al. (26)After PCI, SCADInvasive angiogramDERanolazine750 mg/day0.7581.330.161.390.29Safdar et al. (27)CMDCTAPETRanolazine1,000C2,000 mg/day1211.60.31.90.4Villano et al. (23)CMDInvasive angiogramDERanolazine750 mg/day1151.990.61.860.5Zhang et al. (28)Cardiac syndrome XInvasive angiogramDEDiltiazem90 mg/day3.25222.190.582.50.72Fluvastatin40 mg/day3.25222.020.452.630.62Pauly et al. (9)CMDInvasive angiogramIC DopplerQuinapril40C80 mg/day4292.520.362.770.5Iino et al. (29)After PCI in RCA, patients without stenosis in LADInvasive angiogramIC DopplerCandesartan4C8 mg/day6.5141.990.23.370.27Chen et al. (21)Cardiac syndrome XInvasive angiogramIC DopplerEnalapril10 mg/day2103.260.564.010.65Toyama et al. (30)HTMedical historyCMRIOlmesartan10C40 mg/day6.5101.913.11.1Amlodipin2.5C10 mg/day6.5102.20.82.40.9Kamezaki et al. (31)HTClinical history and treadmill exercise testDEValsartan40C80 mg/day1.582.340.383.041.09Nifedipine20C40 mg/day1.582.720.222.410.4Parodi et al. (32)HTInvasive angiogramPETEnalapril10C40 mg/day6.5102.420.722.370.59Verapamil240C480 mg/day6.5102.740.83.731.79Hinoi et al. (33)HTMedical historyDETelmisartan40 mg/day5202.40.42.90.4Nifedipine20 mg/day5202.50.32.50.3Xiaozhen et al. (34)HT&LVHInvasive angiogramDECarvedilol10 mg/day6.5282.310.313.160.67Metoprolol50 mg/day6.5292.320.292.460.58Gullu et al. (35)HTMedical historyDENebivolol5 mg/day2302.450.482.560.52Atenolol50 mg/day2302.460.442.210.4Buus et al. (36)HTMedical historyPETPerindopril4C8 mg/day12152.390.172.640.17Atenolol50C100 mg/day12152.310.162.090.19Yokoyama et al. (37)HCEchocardiography and treadmill exercise testPETSimvastatin5C10 mg/day10222.360.673.181.22Pravastatin10C20 mg/day10222.210.722.320.64Lario et al. (38)HCCTADEAtorvastatin40C80 mg/day3162.780.713.430.66Kawata et al. (39)DMEchocardiography and treadmill exercise testDETemocapril2 mg/day1122.740.283.310.36Candesartan8 mg/day1122.650.32.710.43Akinboboye et al. (40)HT&LVHClinical history and PETPETLisinopril10 mg/day1192.413.71.1NONRANDOMIZEDGalderisi et al. (41)HTMedical historyDENebivolol5 mg/day3202.070.162.20.243Eshtehardi et al. (42)SCADInvasive angiogramIC DopplerAtorvastatin40C80 mg/day6.5202.320.442.530.89Motz and Strauer (43)HT with microvascular anginaInvasive angiogramIC DopplerEnalapril10C20 mg/day3152.20.63.31.2Caliskan et al. (44)Slow coronary flowInvasive angiogramDEAtorvastatin20 mg/day2201.950.382.540.56Galderisi et al. (45)HTMedical historyDENebivolol5 mg/day1141.890.312.120.33Lethen et al. (46)HTClinical history, ECG, and DEPETIrbesartan600 mg/day3182.870.423.780.32Toms et al. (47)HTClinical history, ECG, and DEDECandesartan16 mg/day3223.113.561Sun et al. (48)HT, HCMedical historyDERosuvastatin10 mg/day12553.160.443.310.42Jensen et al. (49)HCInvasive.During TTDE, PET, and CMR, coronary flow velocity at rest and maximal hyperemia induced by administration of intravenous adenosine (140 lg/kg/min) are recorded to measure CFR (79). not associated with improved CFR. Conclusions: Therapy with ACEIs, ARBs, and statins was associated with improved CFR in patients with confirmed or suspicious CMD. CCBs also improved CFR among patients followed for 6C12 months. Beta-blocker and ranolazine had no impact on CFR. 0.05 was considered statistically significant. Results Study Selection and Characteristics A total of 5,723 references were identified from database search analyses. Of these, 5,537 were excluded during title and abstract level screening (Figure 1). Of the remaining 186 studies, 140 were excluded for the following reasons: obstructive CAD HDAC-IN-7 (= 54), unclear or missing CFR data (= 21); use of intravenous drugs (= 47); and incomplete information (= 18). Forty-six of the remaining studies reported CFR data and did not meet any other exclusion criteria, of which 28 were randomized controlled trials and 18 were non-randomized studies. The study characteristics are presented in Table 1, and the clinical characteristics of patients are presented in Supplementary Table 2. A total of 845 patients, ranging from 8 to 55 participants per trial, were ultimately included who received coronary microvascular function assessments before and after administration of oral medications. CFR is feasible for coronary microvascular function evaluation (1), and we therefore collected CFR data as an indicator of coronary microvascular function. At present, there is no uniform gold standard for CFR detection methods. Methods for measuring CFR included intracoronary (IC) Doppler flow wire (= 6), cardiac magnetic HDAC-IN-7 resonance imaging (CMRI) (= 2), positron emission tomography (PET) (= 11), and Doppler echocardiography (DE) (= 27). Methods for obtaining stenosis of epicardial coronary artery included invasive angiography (= 21), CT coronary angiography (= 6), medical history (= 8), and DE and treadmill exercise test (= 11). Follow-up duration varied from 0.75 to 12 months. Table 1 Study characteristics. thead th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Author /th th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Diagnosis /th th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Method for CAD /th th valign=”top” align=”still left” rowspan=”1″ colspan=”1″ Way for CFR /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Medications /th th valign=”best” align=”still left” rowspan=”1″ colspan=”1″ Dosage /th th valign=”best” align=”middle” rowspan=”1″ colspan=”1″ Follow-up a few months /th th valign=”best” align=”middle” rowspan=”1″ colspan=”1″ em N /em /th th valign=”best” align=”middle” colspan=”2″ design=”border-bottom: slim solid #000000;” rowspan=”1″ Pre-CFR /th th valign=”best” align=”middle” colspan=”2″ design=”border-bottom: slim solid #000000;” rowspan=”1″ Post-CFR /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th valign=”best” align=”middle” colspan=”2″ rowspan=”1″ Mean SD /th th valign=”best” align=”middle” colspan=”2″ rowspan=”1″ Mean SD /th /thead RANDOMIZEDGolino et al. (26)After PCI, SCADInvasive angiogramDERanolazine750 mg/time0.7581.330.161.390.29Safdar et al. (27)CMDCTAPETRanolazine1,000C2,000 mg/time1211.60.31.90.4Villano et al. (23)CMDInvasive angiogramDERanolazine750 mg/time1151.990.61.860.5Zsuspend et al. (28)Cardiac symptoms XInvasive angiogramDEDiltiazem90 mg/time3.25222.190.582.50.72Fluvastatin40 mg/time3.25222.020.452.630.62Pauly et al. (9)CMDInvasive angiogramIC DopplerQuinapril40C80 mg/time4292.520.362.770.5Iino et al. (29)After PCI in RCA, sufferers without stenosis in LADInvasive angiogramIC DopplerCandesartan4C8 mg/time6.5141.990.23.370.27Chen et al. (21)Cardiac symptoms XInvasive angiogramIC DopplerEnalapril10 mg/time2103.260.564.010.65Toyama et al. (30)HTMedical historyCMRIOlmesartan10C40 mg/time6.5101.913.11.1Amlodipin2.5C10 mg/day6.5102.20.82.40.9Kamezaki et al. (31)HTClinical background and treadmill workout testDEValsartan40C80 mg/time1.582.340.383.041.09Nifedipine20C40 mg/time1.582.720.222.410.4Parodi et al. (32)HTInvasive angiogramPETEnalapril10C40 mg/time6.5102.420.722.370.59Verapamil240C480 mg/time6.5102.740.83.731.79Hinoi et al. (33)HTMedical historyDETelmisartan40 mg/time5202.40.42.90.4Nifedipine20 mg/time5202.50.32.50.3Xiaozhen et al. (34)HT&LVHInvasive angiogramDECarvedilol10 mg/time6.5282.310.313.160.67Metoprolol50 mg/time6.5292.320.292.460.58Gullu et al. (35)HTMedical historyDENebivolol5 mg/time2302.450.482.560.52Atenolol50 mg/time2302.460.442.210.4Buus et al. (36)HTMedical historyPETPerindopril4C8 mg/time12152.390.172.640.17Atenolol50C100 mg/day12152.310.162.090.19Yokoyama et al. (37)HCEchocardiography and fitness treadmill workout testPETSimvastatin5C10 mg/time10222.360.673.181.22Pravastatin10C20 mg/time10222.210.722.320.64Lario et al. (38)HCCTADEAtorvastatin40C80 mg/time3162.780.713.430.66Kawata et al. (39)DMEchocardiography and fitness treadmill workout testDETemocapril2 mg/time1122.740.283.310.36Candesartan8 mg/day1122.650.32.710.43Akinboboye et al. (40)HT&LVHClinical background and PETPETLisinopril10 mg/time1192.413.71.1NONRANDOMIZEDGalderisi et al. (41)HTMedical historyDENebivolol5 mg/time3202.070.162.20.243Eshtehardi et al. (42)SCADInvasive angiogramIC DopplerAtorvastatin40C80 mg/time6.5202.320.442.530.89Motz and Strauer (43)HT with microvascular anginaInvasive angiogramIC DopplerEnalapril10C20 mg/time3152.20.63.31.2Caliskan et al. (44)Decrease coronary flowInvasive angiogramDEAtorvastatin20 mg/time2201.950.382.540.56Galderisi et al. (45)HTMedical historyDENebivolol5 mg/time1141.890.312.120.33Lethen et al. (46)HTClinical background, ECG, and DEPETIrbesartan600 mg/time3182.870.423.780.32Toms et al. (47)HTClinical background, ECG, and DEDECandesartan16 mg/time3223.113.561Sun et al. (48)HT, HCMedical historyDERosuvastatin10 mg/time12553.160.443.310.42Jensen et al. (49)HCInvasive angiogramIC DopplerSimvastatin40 mg/time12362.50.62.60.6Baller et al. (50)AnginaInvasive angiogramPETSimvastatin20 mg/time6.5232.20.62.640.6Schwartzkopff et al. (51)HTInvasive angiogramDEPerindopril4C8 mg/time12142.10.63.51.9Vogt and Strauer (52)HTInvasive angiogramDEDiltiazem242 35 mg/time12162.460.83.291.22Isradipine5.3 0.9 mg/day12152.330.553.30.87Fujimoto et al. (53)HCMedical.Of the rest of the 186 studies, 140 were excluded for the next factors: obstructive CAD (= 54), unclear or missing CFR data (= 21); usage of intravenous medications (= 47); and imperfect details (= 18). 0.51C1.58). Beta-blocker (SMD: 0.24; 95% CI: ?0.39C0.88) and ranolazine treatment (SMD: 0.31; 95% CI: ?0.39C1.01) weren’t connected with improved CFR. Conclusions: Therapy with ACEIs, ARBs, and statins was connected with improved CFR in sufferers with verified or dubious CMD. CCBs also improved CFR among sufferers implemented for 6C12 a few months. Beta-blocker and ranolazine acquired no effect on CFR. 0.05 was considered statistically significant. Outcomes Research Selection and Features A complete of 5,723 personal references had been identified from data source search analyses. Of the, 5,537 had been excluded during name and abstract level testing (Physique 1). Of the remaining 186 studies, 140 were excluded for the following reasons: obstructive CAD (= 54), unclear or missing CFR data (= 21); use of intravenous drugs (= 47); and incomplete information (= 18). Forty-six of the remaining studies reported CFR data and did not meet any other exclusion criteria, of which 28 were randomized controlled trials and 18 were non-randomized studies. The study characteristics are offered in Table 1, and the clinical characteristics of patients are offered in Supplementary Table 2. A total of 845 patients, ranging from 8 to 55 participants per trial, were ultimately included who received coronary microvascular function assessments before and after administration of oral medications. CFR is feasible for coronary microvascular function evaluation (1), and we therefore collected CFR data as an indication of coronary microvascular function. At present, there is no uniform gold standard for CFR detection methods. Methods for measuring CFR included intracoronary (IC) Doppler circulation wire (= 6), cardiac magnetic resonance imaging (CMRI) (= 2), positron emission tomography (PET) (= 11), and Doppler echocardiography (DE) (= 27). Methods for obtaining stenosis of epicardial coronary artery included invasive angiography (= 21), CT coronary angiography (= 6), medical history (= 8), and DE and treadmill machine exercise test (= 11). Follow-up duration varied from 0.75 to 12 months. Table 1 Study characteristics. thead th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Author /th th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Diagnosis /th th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Method for CAD /th th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Method for CFR /th th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Drugs /th th valign=”top” align=”left” rowspan=”1″ colspan=”1″ Dose /th th valign=”top” align=”center” rowspan=”1″ colspan=”1″ Follow-up months /th th valign=”top” align=”center” rowspan=”1″ colspan=”1″ em N /em /th th valign=”top” align=”center” colspan=”2″ style=”border-bottom: thin solid #000000;” rowspan=”1″ Pre-CFR /th th valign=”top” align=”center” colspan=”2″ style=”border-bottom: thin solid #000000;” rowspan=”1″ Post-CFR /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th rowspan=”1″ colspan=”1″ /th th valign=”top” align=”center” colspan=”2″ rowspan=”1″ Mean SD /th th valign=”top” align=”center” colspan=”2″ rowspan=”1″ Mean SD /th /thead RANDOMIZEDGolino et al. (26)After PCI, SCADInvasive angiogramDERanolazine750 mg/day0.7581.330.161.390.29Safdar et al. (27)CMDCTAPETRanolazine1,000C2,000 mg/day1211.60.31.90.4Villano et al. (23)CMDInvasive angiogramDERanolazine750 mg/day1151.990.61.860.5Zhang et al. (28)Cardiac syndrome XInvasive angiogramDEDiltiazem90 mg/day3.25222.190.582.50.72Fluvastatin40 mg/day3.25222.020.452.630.62Pauly et al. (9)CMDInvasive angiogramIC DopplerQuinapril40C80 mg/day4292.520.362.770.5Iino et al. (29)After PCI in RCA, patients without stenosis in LADInvasive angiogramIC DopplerCandesartan4C8 mg/day6.5141.990.23.370.27Chen et al. (21)Cardiac syndrome XInvasive angiogramIC DopplerEnalapril10 mg/day2103.260.564.010.65Toyama et al. (30)HTMedical historyCMRIOlmesartan10C40 mg/day6.5101.913.11.1Amlodipin2.5C10 mg/day6.5102.20.82.40.9Kamezaki et al. (31)HTClinical history and treadmill exercise testDEValsartan40C80 mg/day1.582.340.383.041.09Nifedipine20C40 mg/day1.582.720.222.410.4Parodi et al. (32)HTInvasive angiogramPETEnalapril10C40 mg/day6.5102.420.722.370.59Verapamil240C480 mg/day6.5102.740.83.731.79Hinoi et al. (33)HTMedical historyDETelmisartan40 mg/day5202.40.42.90.4Nifedipine20 mg/day5202.50.32.50.3Xiaozhen et al. (34)HT&LVHInvasive angiogramDECarvedilol10 mg/day6.5282.310.313.160.67Metoprolol50 mg/day6.5292.320.292.460.58Gullu et al. (35)HTMedical historyDENebivolol5 mg/day2302.450.482.560.52Atenolol50 mg/day2302.460.442.210.4Buus et al. (36)HTMedical historyPETPerindopril4C8 mg/day12152.390.172.640.17Atenolol50C100 mg/day12152.310.162.090.19Yokoyama et al. (37)HCEchocardiography and treadmill machine exercise testPETSimvastatin5C10 mg/day10222.360.673.181.22Pravastatin10C20 mg/day10222.210.722.320.64Lario et al. (38)HCCTADEAtorvastatin40C80 mg/day3162.780.713.430.66Kawata et al. (39)DMEchocardiography and treadmill machine exercise testDETemocapril2 mg/day1122.740.283.310.36Candesartan8 mg/day1122.650.32.710.43Akinboboye et al. (40)HT&LVHClinical history and PETPETLisinopril10 mg/day1192.413.71.1NONRANDOMIZEDGalderisi et al. (41)HTMedical historyDENebivolol5 mg/day3202.070.162.20.243Eshtehardi et al. (42)SCADInvasive angiogramIC DopplerAtorvastatin40C80 mg/day6.5202.320.442.530.89Motz and Strauer (43)HT with microvascular anginaInvasive angiogramIC DopplerEnalapril10C20 mg/day3152.20.63.31.2Caliskan et al. (44)Decrease coronary flowInvasive angiogramDEAtorvastatin20 mg/day time2201.950.382.540.56Galderisi et al. (45)HTMedical historyDENebivolol5 mg/day time1141.890.312.120.33Lethen et al. (46)HTClinical background, ECG, and DEPETIrbesartan600 mg/day time3182.870.423.780.32Toms et al. (47)HTClinical background, ECG, and DEDECandesartan16 mg/day time3223.113.561Sun et al. (48)HT, HCMedical historyDERosuvastatin10 mg/day time12553.160.443.310.42Jensen et al. (49)HCInvasive angiogramIC DopplerSimvastatin40 mg/day time12362.50.62.60.6Baller et al. (50)AnginaInvasive angiogramPETSimvastatin20 mg/day time6.5232.20.62.640.6Schwartzkopff et al. (51)HTInvasive angiogramDEPerindopril4C8 mg/day time12142.10.63.51.9Vogt and Strauer (52)HTInvasive angiogramDEDiltiazem242 35 mg/day time12162.460.83.291.22Isradipine5.3 0.9 mg/day12152.330.553.30.87Fujimoto et al. (53)HCMedical historyDEFluvastatin20 mg/day time31630.53.50.8Stamatelopoulos et al. (54)HTInvasive angiogramDEQuinapril20 mg/day time1152.990.683.360.91Losartan100 mg/day1152.860.543.440.65Kjear et al. (55)DMTreadmill workout testPETLosartan100 mg/day time6.5142.360.242.620.42Kawata et al. (56)DMDE and a home treadmill workout testDETemocapril2 mg/day time1202.780.363.350.46.